{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:26:44Z","timestamp":1760056004931,"version":"build-2065373602"},"reference-count":29,"publisher":"Akademiai Kiado Zrt.","issue":"3","content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study is to detect the carbapenemase type and to determine the <jats:italic>in vitro<\/jats:italic> effects of ceftazidime\/avibactam-colistin, ceftazidime\/avibactam-meropenem and ceftazidime\/avibactam-tigecycline combinations against Carbapenem-Resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> (CRKP) isolates. A total of 35 CRKP isolates were included to the study. The minimum inhibitory concentrations of ceftazidime\/avibactam, meropenem, colistin and tigecycline were determined by broth dilution method. Synergistic effects of ceftazidime\/avibactam-colistin, ceftazidime\/avibactam-meropenem and ceftazidime\/avibactam-tigecycline were investigated by microdilution checkerboard method. Carbapenemase genes (<jats:italic>bla<\/jats:italic><jats:sub>OXA-48<\/jats:sub><jats:italic>, bla<\/jats:italic><jats:sub>NDM<\/jats:sub><jats:italic>, bla<\/jats:italic><jats:sub>KPC<\/jats:sub><jats:italic>, bla<\/jats:italic><jats:sub>IMP<\/jats:sub><jats:italic>, bla<\/jats:italic><jats:sub>VIM<\/jats:sub>) were detected by multiplex PCR. All of the isolates were resistant to meropenem, whereas 77.1% of the isolates were resistant to ceftazidime\/avibactam and 14.3% of the isolates were resistant to colistin.<\/jats:p><jats:p>The carbapenemase genes of the CRKP isolates were determined as 17 OXA-48+NDM, 9 KPC, 6 OXA-48, 1 NDM, 1 KPC+NDM and 1 KPC+OXA-48. Ceftazidime\/avibactam-colistin, ceftazidime\/avibactam-meropenem and ceftazidime\/avibactam-tigecycline combinations were synergistic against 5.7% (2\/35), 17.1% (6\/35), and 5.7% (2\/35) of the isolates, respectively. Ceftazidime\/avibactam-meropenem was the most effective synergistic combination in our study, showing synergism in 17.1% of isolates, however, the synergistic effect varied depending on the CRKP isolate tested.<\/jats:p>","DOI":"10.1556\/030.2025.02686","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T12:32:05Z","timestamp":1758025925000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method"],"prefix":"10.1556","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5399-3374","authenticated-orcid":true,"given":"Serpil","family":"Gen\u00e7","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Medical Microbiology, K\u00fctahya Health Sciences University, K\u00fctahya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayten Nur","family":"Uzun","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Microbiology, K\u00fctahya Health Sciences University, K\u00fctahya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilal","family":"Tanriverdi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Microbiology, K\u00fctahya Health Sciences University, K\u00fctahya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"B1","series-title":"Antibiotic resistance threats in the United States","author":"CDC.","year":"2019","unstructured":"CDC. Antibiotic resistance threats in the United States 2019. Available from: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"B2","article-title":"2022\u20132023 Y\u0131l\u0131 Y\u0131ll\u0131k Raporu, T\u00fcrkiye Halk Sagl\u0131g\u0131 Kurumu, Sagl\u0131k Bakanl\u0131g\u0131, Ankara","author":"Ulusal Antimikrobiyal Diren\u00e7 Surveyans Sistemi","year":"2025","unstructured":"Ulusal Antimikrobiyal Diren\u00e7 Surveyans Sistemi. 2022\u20132023 Y\u0131l\u0131 Y\u0131ll\u0131k Raporu, T\u00fcrkiye Halk Sagl\u0131g\u0131 Kurumu, Sagl\u0131k Bakanl\u0131g\u0131, Ankara; 2025. https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/mikrobiyoloji-referans-laboratuvarlari-ve-biyolojik-urunler-db\/Dokumanlar\/Raporlar\/UAMDS_2022-2023_Yillik_Raporu.pdf."},{"key":"B3","article-title":"Central Asian and eastern European surveillance of antimicrobial resistance","author":"WHO","year":"2016","unstructured":"WHO. Central Asian and eastern European surveillance of antimicrobial resistance. Annual report; 2016. http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0009\/323568\/CAESAR-Annual-report-2016.pdf."},{"issue":"5","key":"B4","series-title":"J Intern Med","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden T","year":"2015","unstructured":"Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 2015; 277(5): 501\u201312. 10.1111\/joim.12342https:\/\/doi.org\/10.1111\/joim.12342"},{"issue":"9","key":"B5","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dku168","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria","volume":"69","author":"Paul M","year":"2014","unstructured":"Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et\u00a0al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014; 69(9): 2305\u20139. 10.1093\/jac\/dku168https:\/\/doi.org\/10.1093\/jac\/dku168"},{"issue":"7","key":"B6","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik SM","year":"2011","unstructured":"Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et\u00a0al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55(7): 3284\u201394. 10.1128\/AAC.01733-10https:\/\/doi.org\/10.1128\/AAC.01733-10"},{"issue":"11","key":"B7","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing enterobacteriaceae","volume":"73","author":"Sousa A","year":"2018","unstructured":"Sousa A, P\u00e9rez-Rodr\u00edguez MT, Soto A, Rodr\u00edguez L, P\u00e9rez-Landeiro A, Mart\u00ednez-Lamas L, et\u00a0al. Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother 2018; 73(11): 3170\u20133175. 10.1093\/jac\/dky295https:\/\/doi.org\/10.1093\/jac\/dky295"},{"key":"B8","series-title":"Int J Infect Dis","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n JJ","year":"2017","unstructured":"Cast\u00f3n JJ, Lacort-Peralta I, Mart\u00edn-D\u00e1vila P, Loeches B, Tabares S, Temkin L, et\u00a0al. Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing enterobacteriaceae in hematologic patients. Int J Infect Dis 2017; 59: 118\u2013123. 10.1016\/j.ijid.2017.03.021https:\/\/doi.org\/10.1016\/j.ijid.2017.03.021"},{"key":"B9","series-title":"Infect Dis Ther","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40121-021-00479-7","article-title":"Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study","volume":"10","author":"Zheng G","year":"2021","unstructured":"Zheng G, Zhang J, Wang B, et\u00a0al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther 2021; 10: 1699\u20131713. 10.1007\/s40121-021-00479-7https:\/\/doi.org\/10.1007\/s40121-021-00479-7"},{"issue":"6","key":"B10","series-title":"WIREs Mech Dis","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1571","article-title":"Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam","volume":"14","author":"Xiong L","year":"2022","unstructured":"Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, et\u00a0al. Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam. WIREs Mech Dis 2022; 14(6): e1571. 10.1002\/wsbm.1571https:\/\/doi.org\/10.1002\/wsbm.1571"},{"key":"B11","article-title":"The European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters","author":"EUCAST","year":"2024","unstructured":"EUCAST. The European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0; 2024. Available online: http:\/\/www.eucast.org, Accessed 22 February 2025."},{"key":"B12","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail S","year":"2019","unstructured":"Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et\u00a0al. Evaluation of the synergy of ceftazidime avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63: e00779-19. 10.1128\/AAC.00779-19https:\/\/doi.org\/10.1128\/AAC.00779-19"},{"issue":"1","key":"B13","series-title":"J Clin Microbiol","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1128\/JCM.43.1.140-143.2005","article-title":"Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis","volume":"43","author":"Orhan G","year":"2005","unstructured":"Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43(1): 140\u20133. 10.1128\/JCM.43.1.140-143.2005https:\/\/doi.org\/10.1128\/JCM.43.1.140-143.2005"},{"issue":"4","key":"B14","series-title":"Flora","first-page":"219","article-title":"Antibiyotik Kombinasyonlar\u0131n\u0131n \u0130n vitro Etkinli\u011finin Saptanmas\u0131","volume":"4","author":"Bal \u00c7","year":"1999","unstructured":"Bal \u00c7. Antibiyotik Kombinasyonlar\u0131n\u0131n \u0130n vitro Etkinli\u011finin Saptanmas\u0131. Flora 1999; 4(4): 219\u2013229."},{"issue":"3","key":"B15","series-title":"Mikrobiyol Bul","first-page":"410","article-title":"Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?","volume":"46","author":"\u00d6zseven AG","year":"2012","unstructured":"\u00d6zseven AG, Sesli \u00c7etin E, \u00d6zseven L. Do different interpretative methods used for evaluation of checkerboard synergy test affect the results? Mikrobiyol Bul 2012; 46(3): 410\u201320."},{"key":"B16","series-title":"J\u00a0Infect Chemother","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jiac.2021.10.009","article-title":"Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: the first K. pneumoniae isolates co-producing OXA-48\/KPC and KPC\/NDM in Turkey","volume":"28","author":"Gen\u00e7 S","year":"2022","unstructured":"Gen\u00e7 S, Kolayl\u0131 F, Yaz\u0131c\u0131 Oz\u00e7elik E. Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: the first K. pneumoniae isolates co-producing OXA-48\/KPC and KPC\/NDM in Turkey. J\u00a0Infect Chemother 2022; 28: 192\u2013198. 10.1016\/j.jiac.2021.10.009https:\/\/doi.org\/10.1016\/j.jiac.2021.10.009"},{"key":"B17","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","volume":"27","author":"Tacconelli E","year":"2017","unstructured":"Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 27. World Health Organization; 2017."},{"issue":"1","key":"B18","series-title":"Mikrobiyol Bul","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5578\/mb.10695","article-title":"Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey","volume":"50","author":"\u00c7akar A","year":"2016","unstructured":"\u00c7akar A, Aky\u00f6n Y, G\u00fcr D, Karatuna O, \u00d6\u011f\u00fcn\u00e7 D, \u00d6zhak BB, et\u00a0al. Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey. Mikrobiyol Bul 2016; 50(1): 21\u201333. 10.5578\/mb.10695https:\/\/doi.org\/10.5578\/mb.10695"},{"issue":"2","key":"B19","series-title":"Mikrobiyol Bul","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5578\/mb.20229804","article-title":"Evaluation of in vitro efficacy of ceftazidime-avibactam, meropenem, and colistin single and binary combinations against carbapenem resistant Klebsiella pneumoniae strains isolated from various clinical specimens","volume":"56","author":"K\u00f6le M","year":"2022","unstructured":"K\u00f6le M, Sesli \u00c7etin E, \u015eirin MC, Cicio\u011flu Ar\u0131do\u011fan B. Evaluation of in vitro efficacy of ceftazidime-avibactam, meropenem, and colistin single and binary combinations against carbapenem resistant Klebsiella pneumoniae strains isolated from various clinical specimens. Mikrobiyol Bul 2022; 56(2): 230\u2013250. 10.5578\/mb.20229804https:\/\/doi.org\/10.5578\/mb.20229804"},{"issue":"3","key":"B20","series-title":"Int J Antimicrob Agents","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime-avibactam against gram-negative isolates collected in 18 European countries, 2015-2017","volume":"56","author":"Stone GG","year":"2020","unstructured":"Stone GG, Seifert H, Nord CE. In vitro activity of ceftazidime-avibactam against gram-negative isolates collected in 18 European countries, 2015-2017. Int J Antimicrob Agents 2020; 56(3): 106045. 10.1016\/j.ijantimicag.2020.106045https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106045"},{"issue":"1","key":"B21","series-title":"Sci Rep","article-title":"Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta","volume":"9","author":"Schmid A","year":"2019","unstructured":"Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta. Sci Rep 2019; 9(1): 15290."},{"key":"B22","series-title":"J Chemother","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/1120009X.2020.1761172","article-title":"Evaluation of the synergy of ceftazidime\/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales","volume":"32","author":"Mataraci KE","year":"2020","unstructured":"Mataraci KE, Yilmaz M, Istanbullu Tosun A, \u00d6zbek \u00c7elik B. Evaluation of the synergy of ceftazidime\/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. J Chemother 2020; 32: 171\u2013178. 10.1080\/1120009X.2020.1761172https:\/\/doi.org\/10.1080\/1120009X.2020.1761172"},{"issue":"6","key":"B23","series-title":"Microbiol Spectr","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00107-24","article-title":"Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae","volume":"12","author":"Wu Y","year":"2024","unstructured":"Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, et\u00a0al. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr 2024; 12(6): e0010724. 10.1128\/spectrum.00107-24https:\/\/doi.org\/10.1128\/spectrum.00107-24"},{"issue":"s5","key":"B24","series-title":"Clin Infect Dis","first-page":"S333","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher AK","year":"2005","unstructured":"Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41(s5): S333\u2013S40."},{"issue":"10","key":"B25","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of Ceftazidimeavibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries RM","year":"2015","unstructured":"Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, et\u00a0al. First report of Ceftazidimeavibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother, 2015; 59(10), 6605\u20136607. 10.1128\/AAC.01165-15https:\/\/doi.org\/10.1128\/AAC.01165-15"},{"issue":"1","key":"B26","series-title":"Antimicrob Resist Infect Control","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)","volume":"9","author":"Zhang H","year":"2020","unstructured":"Zhang H, Xu Y, Jia P, Zhu Y, Zhang G, Zhang J, et\u00a0al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016). Antimicrob Resist Infect Control, 2020; 9(1), 166. 10.1186\/s13756-020-00829-zhttps:\/\/doi.org\/10.1186\/s13756-020-00829-z"},{"key":"B27","series-title":"Front Microbiol","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1519319","article-title":"Effectiveness of antimicrobial agent combinations against carbapenem-producing Klebsiella pneumoniae with KPC variants in China","volume":"15","author":"Liu C","year":"2025","unstructured":"Liu C, Wu Y, Zhang Y, Yan Z, Gu D, Zhou H, et\u00a0al. Effectiveness of antimicrobial agent combinations against carbapenem-producing Klebsiella pneumoniae with KPC variants in China. Front Microbiol 2025; 15: 1519319. 10.3389\/fmicb.2024.1519319https:\/\/doi.org\/10.3389\/fmicb.2024.1519319"},{"key":"B28","series-title":"Front Med","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fmed.2023.1249030","article-title":"In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime avibactam monotherapy with ceftazidime avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review","author":"Aslan AT","year":"2023","unstructured":"Aslan AT, Ezure Y, Horcajada JP, Harris PNA, Paterson DL. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime avibactam monotherapy with ceftazidime avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review. Front Med 2023: 10: 1249030. 10.3389\/fmed.2023.1249030https:\/\/doi.org\/10.3389\/fmed.2023.1249030"},{"key":"B29","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases Society of America 2022 guidance on the treatment of extended Spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma PD","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases Society of America 2022 guidance on the treatment of extended Spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75: 187\u2013212. 10.1093\/cid\/ciac268https:\/\/doi.org\/10.1093\/cid\/ciac268"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/72\/3\/article-p220.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/72\/3\/article-p220.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/72\/3\/article-p220.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:47:05Z","timestamp":1759996025000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/72\/3\/article-p220.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":29,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/030.2025.02686","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"type":"print","value":"1217-8950"},{"type":"electronic","value":"1588-2640"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}